节点文献

HDMTX-CF治疗抗药性恶性肿瘤及血药浓度测定

HDMTX--CF USED IN THE REFRACTORY MALIGNANT TUMORS AND MTX PLASMA LEVEL DETERMINED

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 金杏泉孙曾一

【Author】 Jin Xing-quan et al

【机构】 上海医科大学肿瘤医院化疗科上海医科大学肿瘤医院化疗科

【摘要】 <正> 1966年Djerassi首先应用大剂量氨甲喋呤治疗抗药性白血病,至今已较广泛用于急性白血病、非何杰金淋巴瘤、骨肉瘤和其它实体瘤的治疗。最近报道最大剂量已达30g/m~2以上。本文报道采用大剂量氨甲喋呤合并甲酰四氢叶酸钙(以下简称HDMTX-CF)治疗11例晚期抗药性恶性肿瘤,其中6例进行了MTX血药浓度的监测。

【Abstract】 We studied the use of High-Dose Methotrexate(0. 5-6. 0g) with citrovorum factor(RDMTX-CF) in 11 patients with advanced refractory malignant lymphoma andother solid tumors and determined the plasma concentration of MTX at 0,24, 48 and72h after its administration in six patients. Our preliminary results suggest thatHDMTX-CF may be useful as salvage therapy in patients with resistant-conventionalchemotherapy malignant lymphoma. and breast carcinoma and also as postoperativeadjuvant chemotherapy in cases with osteogenic sarcoma. The data further confirm thatthe lethal toxicity of RDMTX-CF is mainly related to the clearance of MTX from body.

  • 【被引频次】1
  • 【下载频次】15
节点文献中: 

本文链接的文献网络图示:

本文的引文网络